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SUMMARY 
The mixed agonist-antagonist analgesics buprenorphine, butorphanol. 
nalbuphine, pentazocine and picenadol were compared to the prototype 
mu and kappa agonists morphine and Mr 2033, respectively, in the following 
tests in rhesus monkeys: overt behavioral effects upon acute administration 
in drug-naive animals; discriminative stimulus properties in monkeys trained 
to respond to either etorphine or ethylketazocine; self-administration of 
the test agent relative to codeine; single dose suppression and precipitation 
in withdrawn and non-withdrawn morphine-dependent monkeys, respec- 
tively; and primary addiction studies in drug-naive animals. Whereas both 
buprenorphine and nalbuphine precipitate withdrawal in morphine-depen- 
dent monkeys, withdrawal following chronic administration of buprenor- 
phine resulted in no observable signs of abstinence, while nalbuphine with- 
drawal was similar to that seen in morphine-dependent monkeys. Butor- 
phanol, pentazocine and picenadol all produced mild dependence of the 
kappa-type; that is, natural withdrawal behavior similar to that seen follow- 
ing chronic Mr 2033 administration. 
Key words: Mixed agonist-antagonist analgesic - Buprenorphine - Butor- 
phanol - Morphine - Mr 2033 (UM 1072) - Nalbuphine -- Pentazocine ~ 
Picenadol - Rhesus monkey - Dependence 
INTRODUCTION 
The profile of action of morphine has been well characterized in rhesus 
monkeys [e.g., 1,2]. Compounds with morphine-like agonist actions share 
the capacities to produce discriminative stimulus effects similar to morphine 
or etorphine, to reinforce responding and to suppress withdrawal in mor- 
phine-dependent monkeys. These properties are dose-dependent, stereo- 
selective and naloxone-sensitive. Whereas the profile of action of kappa 
agonists is not as well defined, UM 1072 (Mr 2033), an N-furyl-substituted 
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benzomorphan, can be used as a prototype kappa agonist. The effects of 
UM 1072 are different from those of morphine in that it does not share 
morphine-like discriminative effects, reinforced responding occurs only at 
low rates and it does not substitute for morphine in dependent monkeys 
[ 11. UM 1072 does share discriminative effects with ethylketocyclazocine, 
however, in a dose-related, stereoselective and naloxone-sensitive manner 
[ 31. Furthermore, chronic administration of UM 1072 produces dependence 
demonstrated by a withdrawal syndrome which is qualitatively different 
from that seen following chronic morphine administration. Thus, it is 
possible to clearly distinguish between opiate agonists at mu and kappa 
receptors. However, there are some opioids which do not have a clear-cut 
profile of effects. Mixed agonist-antagonist analgesics may or may not 
suppress or precipitate morphine withdrawal, depending on the dose of 
mixed agonist-antagonist and the duration of morphine dependence or 
abstinence. Furthermore, chronic administration of these compounds 
may or may not produce dependence of either the mu- or kappa-type. 
The effects of five selected mixed agonist-antagonist analgesics will be 
discussed in relation to their activities in the following tests in rhesus 
monkeys: (1) overt behavioral effects upon acute administration to drug- 
naive animals; (2) discriminative stimulus properties in monkeys trained 
to respond on the drug key after (a) etorphine or (b) ethylketazocine; 
(3) self-administration of the test agent relative to codeine; (4) single dose 
suppression and precipitation tests in morphinedependent monkeys; and 
(5) primary addiction studies in drug-naive monkeys. These five types of 
studies will be discussed in detail in turn. Morphine, as a prototype mu 
agonist, and UM 1072 (Mr 2033), as a prototype kappa agonist, are in- 
cluded for the purpose of comparison. The compounds selected for char- 
acterization are: buprenorphine, butorphanol, nalbuphine, pentazocine 
and picenadol. Their classification in terms of agonist actions at mu or 
kappa receptors, as well as their opiate antagonist effects will be discussed. 
Emphasis will be placed on the substitution and primary dependence studies. 
ACUTE EFFECTS IN NORMAL MONKEYS 
Normal (drug-naive) rhesus monkeys housed in groups of 4-6 were 
trained to receive subcutaneous injections. They were monitored by two 
experienced observers familiar with the individual animals. The appear- 
ance and behavior of the monkeys were noted by checking the presence 
of signs on score sheets. Stupor (the response of the monkeys to external 
stimuli), muscle relaxation (the appearance of the monkeys when stationary) 
and ataxia (the facility of the monkeys when moving) scores were given 
according the descriptions in Table I. It is not possible to distinguish between 
mu and kappa opioids by this test. Thus, morphine and UM 1072 both 
produced stupor and muscle relaxation in a dose-related manner (Figs. 1 
and 2). However, naloxone reversibility indicates opiate receptor mediation 
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TABLE I 
SCALES BY WHICH MONKEYS WERE GRADED FOR STUPOR (ACCORDING TO 
THE ANIMALS’ RESPONSE TO EXTERNAL STIMULI), GENERAL MUSCLE 
RELAXATION (ACCORDING TO THE POSITION THE MONKEYS TAKE WHEN 
STATIONARY) AND ATAXIA (ACCORDING TO THE FACILITY WITH WHICH 











No observable stupor 
Monkey appears to stare into space 
Monkey is inattentive to ordinary movements of other monkeys 
Monkey is inattentive to ordinary movements of observers 
Monkey responds only to loud noises in room 
Monkey responds only to opening of cage latch 
Monkey responds only to loud noises near his ear 
Monkey responds only to touch 
Muscle relaxation 
No observable muscle relaxation 
Slight facial relaxation; jaw slackening, shoulder droop 
Pronounced facial relaxation; jaw slackening, shoulder droop 
Monkey must brace himself to sit up 
Monkey cannot sit 
Ataxia 
No observable ataxia 
Monkey misses step occasionally 
Monkey misses intended landing spot when jumping 
Monkey falls 
of the overt behavioral effects of a given compound. Buprenorphine, butor- 
phanol, nalbuphine and pentazocine caused dose-related mydriasis, stupor 
and muscle relaxation which could be reversed by naloxone. In contrast, 
the stupor, muscle relaxation and ataxia elicited by chlorpromazine or 
phencyclidine is not antagonized by naloxone (Gmerek, unpublished). 
Picenadol caused irritability as well as muscle relaxation and ataxia in 
normal rhesus monkeys. These effects were only transiently modified 
by naloxone. 
DRUG DISCRIMINATION STUDIES 
Rhesus monkeys were trained to discriminate etorphine (0.00032 mg/kg, 
s.c.) or ethylketazocine (0.0032-0.0056 mg/kg, s.c.) from sham injections 
as described previously [4]. Training and testing was done with a multiple- 
trials procedure. Reinforcement with 10 banana-flavored pellets occurred 
after 100 consecutive responses on the injection-appropriate lever during 
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Fig. 1. The effect of morphine given in cumulative doses every 30 min to rhesus monkeys 
(n = 6) on stupor (top panel) and muscle relaxation (bottom panel). Each horizontal 
segment represents the percent of animals (O-100%) showing the designated level of 
effect as described in Table I. 
Fig. 2. The effect of UM 1072 (Mr 2033) given in cumulative doses every 30 min to 
rhesus monkeys (n = 6) on stupor (top panel) and muscle relaxation (bottom panel) 
as in Fig. 1. 
training, or either lever during testing. A criterion of at least 90% injection- 
appropriate responses on every training trial for 5 consecutive days was 
met prior to the first test. During testing, increasing cumulative doses of 
the test agent were given before consecutive trials of a daily session. 
Table II shows the average dose of test compound which produced at 
least 90% drug-appropriate responding in monkeys trained to discriminate 
(a) etorphine from saline or (b) ethylketazocine from saline. The results 
indicate that buprenorphine, butorphanol and nalbuphine are similar to 
morphine in that they occasioned drug-appropriate responding only in the 
monkeys trained to discriminate etorphine, and not in the ethyketazocine- 
trained animals [ 41. Picendadol did not produce drug-appropriate respond- 
ing in the monkeys trained to discriminate ethylketazocine, but was not 
tested in the etorphine-trained monkeys. Pentazocine is unusual in that 
it did not produce drug-appropriate responding in monkeys trained to 
discriminate ethylketazocine [ 31 or etorphine. 
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TABLE II 
DOSES (mg/kg, s.c.) OF COMPOUNDS REQUIRED TO OCCASION 290% OF TOTAL 
SESSION RESPONSES ON THE DRUG-APPROPRIATE LEVER 
Compound Training Stimuli 
Etorphine vs. saline Ethylketazocine vs. saline 
Buprenorphine [-I ] 
Butorphanol [ 41 
Nalbuphine [A] 







Morphine [ 3 ] 1.0 
UM 1072 [1,3] 0.008 
“Indicates no dose produced 290% drug-appropriate responses 
SELF-ADMINISTRATION STUDIES 
Monkeys were trained to self-inject codeine intravenously (0.32 mg/kg 
per injection) as described previously [4]. Saline was used as a negative 
control. A number of doses of test agent were used until a maximum rate 
of responding was obtained, or until directly observable confounding behav- 
iors (such as stupor) were produced. A fixed-ratio 30 schedule of intra- 
venous drug delivery was used, with a lo-min timeout condition in effect 
after each injection. The monkeys (n = 3) participated in twice daily sessions 
of 13 injections or 130 min, whichever occurred first. 
TABLE III 
DRUG REINFORCED RESPONDING OF MONKEYS DURING SUBSTITUTION 
WITH TEST COMPOUNDS FOR THE TRAINING DRUG (CODEINE; 0.32 mg/kg 
PER INJECTION) 
-. -... 
Compound Rate of responding Optimal rate-maintaining 
(% maintained by dose (mg/kg per 
codeine) injection) 
_~_______. _.~_ _ - 
Buprenorphine [ 4 ] 64 0.10 
Butorphanol [4] 39 0.003 
Nalbuphine [ 41 45 0.03 
Pentazocine 34, 86a 0.01) 0.10 
Picenadol 33 0.10 
Morphine [ 31 57 0.10 
UM 1072 [l] 12 0.001 
aResults from separate studies performed in 1977 and 1982. respectivelg 
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Table III shows the relative potencies and efficacies of the compounds 
under investigation to maintain responding in monkeys trained to self- 
administer codeine. Average control response rates for codeine and saline 
were 2.3 and 0.02 responses/s, respectively [4,5]. Morphine was self-ad- 
ministered at 57% of the rate maintained by codeine [5]. In contrast, the 
kappa agonist UM 1072 was self-administered at a very low rate: only 12% 
of that of codeine; similarly, ethylketazocine is self-administered at only 
3% of the rate maintained by codeine [l]. Buprenorphine maintained a 
high rate of responding; butorphanol was self-administered but at rates 
only slightly higher than that of UM 1072; nalbuphine maintained self- 
administration responding at rates intermediate between the mu-agonists 
buprenorphine and morphine, and the kappa agonists ethylketazocine 
and UM 1072 [4]. Picenadol was self-administered at low rates. The results 
of the self-administration studies with pentazocine are difficult to interpret. 
In earlier studies, pentazocine was self-administered at very low rates. 
However, a few monkeys tested in later studies consistently self-admini- 
stered pentazocine at very high rates: close to those maintained by codeine. 
The effect of pentazocine thus appears to be idiosyncratic in this test. This 
is a novel phenomenon using the drug-reinforced responding protocol in 
that it is unusual to find some monkeys self-administer a compound at high 
rates while others do not self-administer it at all; that is, an all-or-none 
effect. 
EFFECTS IN MORPHINE-DEPENDENT MONKEYS 
Group-housed rhesus monkeys were made dependent by administering 
morphine sulfate (3 mg/kg, s.c.) every 6 h for at least 3 months. Withdrawal 
severity was assessed by two experienced observers familiar with the indi- 
vidual animals, as described previously by Deneau and Seevers [6] and 
Villarreal [ 71. The presence of signs and behaviors were recorded on score 
sheets. Withdrawal scores increase with an increasing number and intensity 
of signs (Table IV). This system integrates into one withdrawal severity 
score the appearance and behavior of the monkeys and their responses to 
handling. The median withdrawal score of 14-h withdrawn morphine- 
dependent monkeys was a ‘4’. Withdrawal was assessed before the first 
injection and at 30-60-min intervals thereafter for 4-5 h. 
The suppression test determines the ability of a compound to overcome 
signs of withdrawal in dependent monkeys deprived of two consecutive 
maintenance doses of morphine. Opiate mu agonists suppress withdrawal 
in 14-h morphine-deprived monkeys in a dose-related manner (Fig. 3), 
whereas kappa agonists do not suppress withdrawal in deprived morphine- 
dependent monkeys at doses which do not cause significant stupor [ 11. 
UM 1072 (0.01-0.3 mg/kg, s.c.) does not suppress withdrawal in morphine- 




SCALE BY WHICH MONKEYS WERE GRADED FOR WITHDRAWAL SEVERITYa 
Withdrawal 
score 









No observable signs of withdrawal 
Apprehension, avoiding one another, shivering, 
irritability, quarreling, fighting, disrupted 
social interactions 
Intention tremor, anorexia, piloerection, muscle 
rigidity, aggression, holding of abdomen, sittting 
on floor, abdominal defense reaction, apprehension 
and aggression during handling 
Extreme restlessness, assumption of peculiar 
postures, severe diarrhea, penile erection and 
masturbation, continual crying, lying on side, 
extreme abdominal cramping, convulsions 
Docility in an excitable animal, death 
aBased on classification of Deneau and Seevers [ 51 and Villarreal [6] with modifications 
by D.E. Gmerek. 
bSigns of withdrawal primarily restricted to appearance and behavior of monkeys in 
their cage. 
‘Signs of withdrawal now involve appearance and behavior of monkeys during handling, 
The precipitation test determines the ability of a compound to elicit 
withdrawal signs in non-withdrawn dependent monkeys and is an indication 
of mu opioid receptor antagonist activity. Naltrexone precipitates with- 
drawal in a dose-related manner when given 2 h after the last morphine 
injection in dependent monkeys (Fig. 4). 
The effects of the compounds under investigation in the single dose 
suppression test is summarized in the middle column of Table V. Buprenor- 
phine did not suppress withdrawal in 14-h morphine-deprived animals 
at doses of 0.001-0.1 mg/kg. Higher doses of buprenorphine (0.17-0.3 
mg/kg) exacerbated withdrawal in abstinent monkeys. Butorphanol was 
similar to buprenorphine in that at low doses (0.4-3.2 mg/kg) it had no 
effect in 14-h withdrawn dependent monkeys; and at higher doses (6.4- 
12.8 mg/kg) caused a mild exacerbation of withdrawal signs. A dose of 
25.6 mg/kg of butorphanol produced convulsions. Nalbuphine exacerbated 
withdrawal at doses of 4-8 mg/kg, whereas lower doses had no effect. 
Pentazocine and picenadol were different from the three other compounds 
in that they neither suppressed nor exacerbated withdrawal at sub-con- 
vulsive doses. Pentazocine and picenadol both caused slight stupor at inter- 
mediate doses. 
The mu antagonist effects of the compounds under investigation were 
identified in non-withdrawn morphine-dependent monkeys, as summarized 
in the right-hand column of Table V. Buprenorphine (0.01-0.32 mg/kg) 
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Fig. 3. The effect of single S.C. doses of morphine sulfate in 14-h withdrawn morphine- 
dependent rhesus monkeys (n = G/dose) over time. Withdrawal scores were determined 
according to Table IV. Controls received no treatment. P.I. = pre-injection 
Fig. 4. The effect of single S.C. doses of naltrexone HCl in non-withdrawn morphine- 
dependent rhesus monkeys (n = G/dose). Withdrawal scores were determined according 
to Table IV. P.I. = pre-injection. 
precipitated withdrawal in a dose-related manner, as did nalbuphine (4-16 
mg/kg). However, butorphanol and pentazocine did not elicit withdrawal 
signs in morphine-dependent monkeys. Picenadol was not tested. 
PRIMARY ADDICTION STUDIES 
The propensity of a given compound to produce physiological depend- 
ence following chronic administration was judged through primary addiction 
studies. Three to six drug-naive rhesus monkeys were injected with the test 
compound every 6 h at the maximum tolerable dose, with the dose in- 
TABLE V 
DOSES (mg/kg, s.c.) OF COMPOUNDS WHICH (1) SUPPRESS 14-H ABSTINENCE 
























aNo suppressing effect on withdrawal signs. 
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creasing as tolerance developed. The objective of the dosing schedule was 
to maintain intoxication by the test compound. After 14 and 16 days of 
chronic drug administration, the monkeys were challenged with a dose 
of 2 mg/kg nalorphine and naloxone, respectively. Chronic administration 
of the test agent continued and the monkeys were again challenged with 
nalorphine and naloxone (2 mg/kg) on days 28 and 30, respectively. Finally, 
after 31-36 days of chronic administration, the test agent was completely 
withdrawn. Signs of withdrawal were noted following nalorphine and nalox- 
one administration, and during natural withdrawal until the monkeys return- 
ed to normal. 
Morphine and IJM 1072 primary addiction studies were performed and 
are used as an indication of dependence of the mu- and kappa-type, respec- 
tively. Morphine, given at a (sub-maximal) dose of 3 mg/kg every 6 h, 
caused a rapid development of dependence. Thus, naloxone administration 
on day 16 of chronic morphine administration produced severe withdrawal, 
with withdrawal scores of 5-6. The signs of withdrawal included miosis, 
an increased rate of respiration, piloerection, vomiting, muscle rigidity and 
tremor, crying and calling out, fighting, extreme irritability while in their 
cage (avoidance of contact with other monkeys, disrupted social order and 
interactions) and during handling (vocalization, avoiding being touched, 
scratching, biting and staying on the floor), and severe abdominal cramping 
(i.e. the monkeys protect and hold their stomachs and assume peculiar 
postures in their cages, and have rigid abdomens when palpated). It should 
be emphasized that the abdominal cramping is a primary guide in grading 
morphine withdrawal. Abrupt withdrawal of morphine after 36 days resulted 
in severe abstinence signs, including convulsions. One out of three monkeys 
died. 
In contrast, chronic UM 1072 administration (0.05-3.2 mg/kg) did not 
result in severe dependence. Naloxone administration on day 16 produced 
signs of general irritability and restlessness (disrupted social order and 
interactions, avoidance of physical contact with other monkeys, continued 
pacing and changing of position). A half-yawn/half-retch behavior was 
frequently seen, as well as piloerection. Although the monkeys appeared 
pale, spent time lying on their sides, and vocalized during handling, they 
did not have abdominal defense reactions to palpation. On day 30 of UM 
1072 administration, naloxone caused extreme restlessness and irritability. 
The monkeys paced and shifted positions constantly. Stretching also occurr- 
ed. The half-yawn/half-retch behavior was frequent. This was often associ- 
ated with a rolling of the tongue within the monkey’s mouth. During hand- 
ling, the monkeys were irritable and combative, but there was no abdominal 
defense reaction to palpation, and no indication of abdominal muscle 
cramping. Abrupt withdrawal of UM 1072 resulted in extreme restlessness 
and irritability, but again there was no abdominal response to palpation. 
The withdrawal syndrome exhibited in UM 1072 dependent monkeys is 
qualitatively different from that seen in morphine-dependent monkeys. 
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The most distinctive signs of UM 1072 withdrawal which are not generally 
seen during morphine withdrawal are the half-yawn/half-retch behavior, 
extreme restlessness (continued pacing), stretching and tongue rolling. 
The highest withdrawal scores given to UM 1072-withdrawn monkeys 
were ‘2s’ on day 4 of abstinence. However, there were mild convulsions 
and one out of three animals died. The monkeys appeared normal after 
5 days of UM 1072 abstinence. Recently, UM 1072 (3 mg/kg per 6 h) 
was administered to 6 monkeys for 6 months. None of the monkeys con- 
vulsed or died during abrupt withdrawal of UM 1072. Otherwise, with- 
drawal was qualitatively similar to that seen in the previous investigation 
(Gmerek, unpublished). 
The results of primary addiction studies with the test compounds are 
summarized in Table VI. The details of each primary addiction study will 
be discussed in turn below. 
Buprenorphine was given every 6 h at doses increasing from 0.08 to 
1.28 mg/kg. There was a rapid development of tolerance to the stupor 
and muscle relaxation produced by this compound. Nalorphine challenge 
had no effect in buprenorphinedependent monkeys. Naloxone caused some 
piloerection, irritability and restlessness, but not enough to justify with- 
drawal scores above zero. Abrupt withdrawal of buprenorphine resulted 
in some restlessness, tremor and tongue movements. However, the monkeys 
did not protect their abdomens while in their cages, nor was there evidence 
TABLE VI 
RESULTS OF PRIMARY ADDICTION STUDIES 
___-- 
Compound Maximum Naloxone- 
dose precipitated 
(mg/kg withdrawal 










Buprenorphine 4.8 None None None 
Butorphanol 24.0 5-6 2-3 kappa 
Nalbuphine 128.0 2-3 2-3 mu 
Pentazocine 48.0 l-2 3 kappa 
Picenadol 160.0 3-4 3-4 kappa 
Morphine 12.0 5-6 6-7 mu 
UM 1072 12.0 l-2 2 kappa 
‘Naloxone (2 mg/kg) given on day 30 of chronic administration. 
bWithdrawal score given according to Table IV. 
‘Peak withdrawal score observed during abrupt withdrawal. 
dWithdrawal of the mu or kappa type as defined by that observed following chronic 
morphine or UM 1072 administration, respectively. 
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during palpation of abdominal cramping. In essence, there were no observ- 
able signs indicative of physiological dependence to buprenorphine. 
Butorphanol was given at doses of 0.8-6.4 mg/kg over a 38 day study. 
Tolerance developed rapidly to the stupor and muscle relaxation produced 
by this compound. Nalorphine administration on days 14 and 31 resulted 
in scratching and general signs of irritability, but abdominal defense re- 
actions never developed. Naloxone, however, elicited severe withdrawal 
on days 16 and 36; the behavior was indistinguishable from that observed 
in morphine-dependent monkeys. Nevertheless, in contrast to what is seen 
in morphine-dependent animals, natural withdrawal from butorphanol 
resulted in only mild signs of abstinence. There was very little abdominal 
defense reaction during handling of these animals. Butorphanol withdrawal 
behavior was more of the UM 1072~type than the morphine-type. Maximum 
withdrawal scores of 2-3 were given at 36 h of butorphanol abstinence. 
The monkeys returned to their normal state after 10 days. 
Nalbuphine was administered at the dose of 32 mg/kg every 6 h for 31 
days. Tolerance developed in terms of the duration of the effects of acute 
nalbuphine (mydriasis, mild stupor and muscle relaxation) and the maxi- 
mum effect observed after a given dose. Challenge with nalorphine had no 
effect, but naloxone administration on days 16 and 29 produced severe 
abstinence behavior. There was only minimal abdominal defense reactions 
during palpation, but all other signs typical of morphine withdrawal were 
seen. Abrupt withdrawal of nalbuphine caused morphine-like abstinence 
behavior, including abdominal defense reactions. Maximum withdrawal 
scores of 2-3 were given at 36-48 h of abstinence. The monkeys returned 
to normal in about 10 days. A weight loss of 0.3 kg was observed during 
the first 3 days of nalbuphine withdrawal; the weight was regained during 
the next week. No monkeys died. 
Pentazocine was given at doses of 2-8 mg/kg to 3 monkeys for 33 days. 
The short duration of action of pentazocine required that it be given every 
4 h in order to maintain intoxication. Tolerance developed to pentazocine- 
induced stupor and muscle relaxation. The monkeys scratched at the site 
IIf pentazocine injection. They also were irritable and excited at the time 
of injection. These signs may be indications of withdrawal occurring be- 
tween injections. Challenge with naloxone on day 14 resulted in irritability, 
piloerection, restlessness, an increased rate of respiration and a half-yawn/ 
half-retch behavior (similar to that seen during UM 1072 withdrawal). 
Challenge with nalorphine on day 16 caused some sedation in addition 
to mild kappa-like withdrawal behavior. Naloxone and nalorphine on days 
28 and 30 elicited UM 1072~like withdrawal behavior which was more 
intense than that observed earlier in the study. Scratching, stretching, 
restlessness, irritability and the half-yawn/half-retch behavior were recorded. 
Abrupt withdrawal of pentazocine also resulted in abstinence behavior 
very similar to that seen during UM 1072 withdrawal. Signs of natural 
withdrawal from pentazocine included irritability, restlessness, scratching, 
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stretching, tongue rolling, the half-yawn/half-retch behavior, holding and 
protecting of the abdomen and abdominal defense reactions during hand- 
ling. Withdrawal scores peaked at 32 h of abstinence. The monkeys reverted 
to their normal state within 1 week. 
Picenadol was given to three monkeys at a dose of 10 mg/kg every 6 h, 
and then 20 mg/kg every 8 h. Tolerance developed to picenadol-induced 
stupor, ataxia, mydriasis and tremors. Nalorphine given on day 14 did not 
elicit any signs of withdrawal, but may have potentiated picenadol-induced 
stupor. Naloxone challenge on day 16 produced mile to moderate signs of 
withdrawal including irritability, apprehension, restlessness, nausea and 
vomiting and a slight increase in the rate of respiration. On day 21 of pi- 
cenadol administration, nalorphine caused some signs of irritability and 
malaise (e.g. lying on side), but withdrawal scores above zero were not 
given. Naloxone was given on day 23 and produced withdrawal behavior 
of moderate severity (scores of 3-4). There was no abdominal defense 
reaction during handling although the monkeys were lying on their sides 
and protecting their abdomens. Abrupt withdrawal of picenadol after 
27 days of administration caused abstinence behavior which was not typical 
of that seen following chronic morphine administration. The monkeys 
were irritable, restless and apprehensive. They had an increased rate of 
respiration, piloerection and tremors. The monkeys displayed tongue rolling 
but very little abdominal defense reaction to palpation. Curiously, mydriasis 
remained evident throughout picenadol withdrawal, whereas morphine and 
UM 1072-withdrawal both cause miosis. Signs of abrupt withdrawal from 
picenadol peaked at 60-66 h with withdrawal scores of 3-4. The monkeys 
returned to their normal states after 2-3 weeks. 
DISCUSSION 
The overall summary of the compounds under investigation is shown in 
Table VII. Each test agent will be discussed in turn. 
Buprenorphine has mu-like agonist effects in drug discrimination and 
self-administration tests [4,8] but precipitates withdrawal in morphine- 
dependent rhesus monkeys. Buprenorphine also has been shown to precipi- 
tate signs of withdrawal in morphinedependent patas monkeys, but not 
in rats [ 93. Thus, buprenorphine is a mixed mu agonist-antagonist. 
The inability of buprenorphine to produce significant physiological 
dependence as measured by naloxone-precipitated or natural withdrawal 
in these studies in similar to what was found in patas monkeys [9] and 
rats [lo], and previously in rhesus monkeys [8]. However, Martin et al. 
[ 111 found that multiple intravenous injections of buprenorphine in chronic 
spinal dogs resulted in a mild but prolonged abstinence syndrome. Buprenor- 
phine also partially suppresses withdrawal in morphine dependent chronic 
spinal dogs [ 121 and in 8-h withdrawn morphine dependent rhesus monkeys 
(Gmerek, unpublished). These studies indicate that buprenorphine does 
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TABLE VII 
SUMMARY OF THE PROFILE OF EFFECTS OF SELECTED COMPOUNDS IN 
RHESUS MONKEYSa 
Compound Shares discriminative Rate of Effect or with- Primary 
effects with Self-Ad- drawal in dependence 
ministration morphine- natural- 
Morphine Ethyl- dependent withdrawal 
ketazocine monkeys type 
sup- Precip- 
presses itates 
Buprenorphine Yes No High No Yes None 
Butorphanol Yes No Low No No kappa 
Nalbuphine Yes No Intermediate No Yes mu 





No Low No kappa 
Morphine Yes 











“In tests described in text. 
“NT, not tested. 
have the potential to produce dependence. The dependence-producing 
capacity of buprenorphine can be demonstrated in rats when buprenorphine 
pretreatment is followed by substitution with morphine. Thus, naloxone- 
precipitated withdrawal signs are observed following a single dose of mor- 
phine in rats pretreated with multiple injections of buprenorphine (but 
not in saline pretreated rats). Buprenorphine thus apparently increases the 
potential of morphine to induce dependence. It has been suggested that the 
few signs of withdrawal which can be observed in direct dependence tests 
with buprenorphine reflect the slow dissociation of this compound from 
opiate receptors [lo]. 
Butorphanol has discriminative stimulus effects equivalent to etorphine 
but not to ethylketazocine in rhesus monkeys [4]. Similarly, in rats, butor- 
phanol generalizes to morphine [ 131 but not to cyclazocine [ 141. In squirrel 
monkeys, however, butorphanol does generalize to cyclazocine [ 151. 
Furthermore, butorphanol exerts kappa-like subjective effects in humans 
[ 161. Butorphanol, like UM 1072, is self-administered by rhesus monkeys 
at only low rates [4]. It also does not substitute for morphine in morphine- 
dependent monkeys; nor does it precipitate withdrawal. In fact, the antag- 
onist action of butorphanol has not been demonstrated in rhesus monkeys, 
but it does antagonize morphine in rodents [17,18]. Naloxone-precipitated 
butorphanol withdrawal is severe, but natural withdrawal from butorphanol 
is mild, and more kappa-like than mu-like. Similarly, when butorphanol 
is self-administered by morphine post-addict rats, substitution of saline for 
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butorphanol results in only mild abstinence signs [ 191. In rats, using a 
schedule-controlled behavior procedure, butorphanol has been classified 
as a kappa agonist and a mu or kappa antagonist (or partial agonist) [ 201. 
However, in rhesus monkeys, butorphanol cannot be clearly classified as 
an agonist with selectivity at either kappa or mu receptors and has very 
weak antagonist activity. 
Nalbuphine has the profile of a mu agonist in discrimination, self-admini- 
stration [4] and primary addiction studies. However, it does not substitute 
for morphine in morphine-dependent monkeys. Rather, it precipitates 
morphine-withdrawal. Nalbuphine is thus a typical mixed mu agonist- 
antagonist in rhesus monkeys. Nalbuphine produced a lower level of depen- 
dence than morphine or pentazocine, however, in morphine post-addict 
rats [19]. 
Pentazocine differs from the other compounds in that it does not have 
ethylketazocine- [ 31 or etorphine-equivalent discriminative effects in rhesus 
monkeys. Pentazocine has idiosyncratic effects in monkeys trained to 
self-administer codeine. Some monkeys will self-administer pentazocine 
at high rates, whereas others tend not to self-administer pentazocine. Penta- 
zocine does not suppress or precipitate morphine withdrawal, but induces 
primary dependence of the kappa type. In fact, this is the only available 
evidence in the rhesus monkey that pentazocine is a kappa agonist. Similar 
to the monkeys results, in rats, withdrawal from chronic pentazocine is 
mild. Unlike monkeys, however, withdrawal in morphine-dependent rats 
is partially suppressed by pentazocine [21]. The antagonist actions of 
pentazocine are very weak in the rhesus monkey; however, pentazocine 
will not antagonize the effect of morphine on schedule-induced responding 
in monkeys [ 221 and only at very high doses will participate withdrawal in 
morphine-dependent monkeys [ 71. Pentazocine apparently acts as a mixed 
kappa agonist-antagonist in the rhesus monkey. Similarly, pentazocine 
has been classified as a weak mu antagonist and a strong kappa and sigma 
agonist in the chronic spinal dog [ 121. 
Very little is known about picenadol, the newest of the compounds 
investigated in this study. It was assumed that picenadol is an opioid, al- 
though the observable agonist actions of acutely administered picenadol 
were resistant to antagonism by naloxone. Picenadol may be similar to 
pentazocine in that, although it produces primary dependence of the kappa 
type, it does not occasion drug-appropriate responding in monkeys trained 
to discriminate ethylketazocine. In a manner also similar to pentazocine, 
it neither suppresses nor precipitates morphine withdrawal. It is self-ad- 
ministered at only low rates; similar to UM 1072. Picenadol may be a mixed 
kappa agonist-antagonist with novel additional properties. 
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